Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

AIM ImmunoTech Reports Additional Patient Data From Single-center Named Patient Program Evaluating Ampligen As Maintenance Therapy For Advanced Pancreatic Cancer Indicating Additional Progression-free And Overall Survival Over Previously Published Data

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) New patient data
byBenzinga Newsdesk
July 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)

New patient data provide further validation for advancing the development of Ampligen for the treatment of late-stage pancreatic cancer

New data were recently presented by Professor C.H.J. van Eijck, MD, PhD of Erasmus Medical Center at the 5th Dutch Multidisciplinary Gastrointestinal Oncology Congress held in Ermelo, Netherlands

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FDA Accepted Eisai-Biogen’s Supplemental Biologics License Application For Leqembi (Lecanemab-IRMB) 100 mg/ml Injection For Intravenous Use, Supporting The Conversion Of The Accelerated Approval Of Leqembi To A Traditional Approval

By Benzinga Newsdesk
March 6, 4:45 AM
The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is currently planning to hold an Advisory Committee to discuss this application

BIIB